DC vaccine for recurrent high-grade gliomas
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a vaccine made from your own immune cells (dendritic cells) to see if it can help control recurrent or progressive high-grade gliomas. It is for people whose brain tumor has returned after standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a WHO grade 3 or 4 glioma (a type of brain tumor) that has come back or grown despite standard treatment.
- You are between 18 and 75 years old.
- Your overall health is good enough that you can manage daily activities—like being up and about, doing light chores.
- Your blood counts and organ function are acceptable (tested ahead of time).
- You do not have active autoimmune disease, HIV, hepatitis, or serious infections.
- You are willing to have a surgery or biopsy to collect a tumor sample and blood for genetic testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment combining an oncolytic virus with a PD-1 inhibitor for people whose high-grade glioma has come back after standard therapy. The virus is injected directly into the tumor through a device placed in the head, and the drug helps your immune system fight the cancer cells.
This early-stage study tests a personalized cancer vaccine designed to prevent glioblastoma (a serious brain tumor) from coming back after surgery and standard treatment. The vaccine aims to train your immune system to recognize and attack any remaining cancer cells.
This trial tests a new cell therapy (P134 cells) for people whose glioblastoma has come back after standard treatments like radiation or chemotherapy. The therapy uses a patient's own immune cells (PBMCs) to target cancer cells that have specific markers (CD44 or CD133). It also requires a small procedure to place a reservoir under the scalp for drug delivery.
This trial tests a new injection called BC008-1A for people with a grade 4 glioma (a type of brain cancer) that has come back after standard treatment. The goal is to see if the drug can help control the tumor and improve outcomes.
This trial tests a radioactive drug that targets a protein on tumor blood vessels to treat glioblastoma that has come back after standard treatment. It may help shrink tumors or slow their growth.
This trial tests a new drug, GC001, injected directly into the tumor in people with high-grade gliomas (WHO grade 3 or 4) that have come back or are growing. It may be an option if standard treatments have stopped working.
Hear when a new WHO Grade III Gliomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.